Ignite Creation Date:
2025-12-24 @ 10:10 PM
Ignite Modification Date:
2026-01-01 @ 1:53 AM
Study NCT ID:
NCT05435235
Status:
SUSPENDED
Last Update Posted:
2024-07-31
First Post:
2022-06-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury
Sponsor:
Albert Einstein Healthcare Network
Organization:
Study Overview
Official Title:
Dapagliflozin in the Prevention of Post-Coronary Intervention Acute Kidney Injury
Status:
SUSPENDED
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Laboratory UNGAL
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DAPA-PCI-AKI
Brief Summary:
To compare the incidence of acute kidney injury (AKI) post percutaneous coronary intervention (PCI) in a Dapagliflozin treated group versus a group managed with the usual standard of care.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?: